Journal of Extracellular Vesicles,
Год журнала:
2025,
Номер
14(2)
Опубликована: Фев. 1, 2025
Abstract
Stochiometric
issues,
encompassing
both
the
quantity
and
heterogeneity
of
extracellular
vesicles
(EVs)
derived
from
tumour
or
other
tissues
in
blood,
pose
important
challenges
across
various
stages
biomarker
discovery
detection,
affecting
integrity
data,
introducing
losses
artifacts
during
blood
processing,
EV
purification
analysis.
These
shape
diagnostic
utility
EVs
especially
within
framework
established
emerging
methodologies.
By
addressing
these
challenges,
we
aim
to
delineate
crucial
parameters
requirements
for
tumour‐specific
more
precisely,
identification
via
based
assays.
Our
endeavour
involves
a
comprehensive
examination
layers
that
mask
confound
traceability
markers
such
as
nucleic
acids
proteins,
focus
on
‘low
prevalence—low
concentration’
scenario.
Finally,
evaluate
advantages
versus
limitations
single‐particle
analysers
over
conventional
bulk
assays,
suggesting
combined
use
capture
interpret
signals,
particular
surface
displayed
may
ultimately
provide
quantitative
information
their
absolute
abundance
distribution.
Cells,
Год журнала:
2022,
Номер
11(11), С. 1845 - 1845
Опубликована: Июнь 5, 2022
Atherosclerotic
cardiovascular
disease
is
the
leading
cause
of
morbidity
and
mortality
all
over
world.
Extracellular
vesicles
(EVs),
small
lipid-bilayer
membrane
released
by
most
cellular
types,
exert
pivotal
multifaceted
roles
in
physiology
disease.
Emerging
evidence
emphasizes
importance
EVs
intercellular
communication
processes
with
key
effects
on
cell
survival,
endothelial
homeostasis,
inflammation,
neoangiogenesis,
thrombosis.
This
review
focuses
as
effective
signaling
molecules
able
to
both
derail
vascular
homeostasis
induce
dysfunction,
plaque
progression,
thrombus
formation
well
drive
anti-inflammation,
repair,
atheroprotection.
We
provide
a
comprehensive
updated
summary
role
development
or
regression
atherosclerotic
lesions,
highlighting
link
between
thrombosis
inflammation.
Importantly,
we
also
critically
describe
their
potential
clinical
use
biomarkers
therapeutic
agents
atherothrombosis.
Nano Letters,
Год журнала:
2023,
Номер
24(1), С. 1 - 8
Опубликована: Дек. 20, 2023
Extracellular
vesicles
and
lipoproteins
are
lipid-based
biological
nanoparticles
that
play
important
roles
in
(patho)physiology.
Recent
evidence
suggests
extracellular
can
interact
to
form
functional
complexes.
Such
complexes
have
been
observed
biofluids
from
healthy
human
donors
various
vitro
disease
models
such
as
breast
cancer
hepatitis
C
infection.
Lipoprotein
components
also
part
of
the
biomolecular
corona
surrounds
contributes
identity.
Potential
mechanisms
relevance
vesicle–lipoprotein
remain
poorly
understood.
This
Review
addresses
current
knowledge
interface
while
drawing
on
pre-existing
liposome
interactions
with
nanoparticles.
There
is
an
urgent
need
for
further
research
lipoprotein–extracellular
vesicle
interface,
which
could
return
mechanistic,
therapeutic,
diagnostic
findings.
Clinical Chemistry,
Год журнала:
2024,
Номер
70(1), С. 165 - 178
Опубликована: Янв. 1, 2024
Substantial
research
has
been
devoted
to
elucidating
the
role
of
extracellular
vesicles
(EVs)
in
different
hallmarks
cancer.
Consequently,
EVs
are
increasingly
explored
as
a
source
cancer
biomarkers
body
fluids.
However,
heterogeneity
EVs,
complexity
fluids,
and
diversity
methods
available
for
EV
analysis,
challenge
development
translation
EV-based
biomarker
assays.
Journal of Agricultural and Food Chemistry,
Год журнала:
2024,
Номер
72(15), С. 8304 - 8331
Опубликована: Апрель 8, 2024
Extracellular
vesicles
(EVs)
are
nano
to-micrometer-sized
sacs
that
released
by
almost
all
animal
and
plant
cells
act
as
intercellular
communicators
transferring
their
cargos
between
the
source
target
cells.
As
a
safe
scalable
alternative
to
conditioned
medium-derived
EVs,
milk-derived
EVs
(miEVs)
have
recently
gained
great
deal
of
popularity.
Numerous
studies
shown
miEVs
intrinsic
therapeutic
actions
can
treat
diseases
enhance
human
health.
Additionally,
they
be
used
natural
drug
carriers
novel
classes
biomarkers.
However,
due
complexity
milk,
successful
translation
from
benchtop
bedside
still
faces
several
unfilled
gaps,
especially
lack
standardized
protocols
for
isolation
high-purity
miEVs.
In
this
work,
comprehensively
reviewing
bovine
studies,
we
provide
an
overview
current
knowledge
research
on
while
highlighting
challenges
enormous
promise
class
theranostics.
It
is
hoped
study
will
pave
way
clinical
applications
addressing
opportunities.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(5), С. 2617 - 2617
Опубликована: Фев. 23, 2024
Standard
non-melanoma
skin
cancer
(NMSC)
treatment
involves
surgery,
recently
combined
with
chemotherapy
or
immunotherapy
in
cases
of
advanced
tumors.
EVs,
including
exosomes,
are
integral
to
carcinogenesis,
and
found
NMSC
releasing
mediators
impacting
tumor
progression.
Nevertheless,
the
precise
intercellular
signaling
role
NMSC-derived
EVs
remains
unclear.
This
review
aims
elucidate
their
potential
diagnosis
treatment.
systematic
encompassed
literature
searches
electronic
databases
from
inception
September
2023,
based
on
certain
inclusion
exclusion
criteria,
addressing
molecular
cargo,
implications
diagnosis,
prognosis,
NMSC.
Key
components
were
identified.
Extracellular
vesicle
(EV)
proteins
RNA
have
emerged
as
diagnostic
biomarkers
EV-based
liquid
biopsy.
Circular
CYP24A1,
known
for
its
stability,
holds
promise
a
biomarker.
Long
noncoding
RNAs
(lincRNA-PICSAR)
Desmoglein
2
(DSg2)
linked
drug
resistance,
serving
prognostic
biomarkers.
EV
being
actively
investigated
delivery
agents.
In
conclusion,
this
showed
that
display
therapeutic
targets
Further
research
is
imperative
fully
comprehend
mechanisms
explore
Bone Reports,
Год журнала:
2022,
Номер
17, С. 101636 - 101636
Опубликована: Ноя. 9, 2022
Mesenchymal
stromal
cells
(MSCs)
have
been
utilized
in
cell
therapy
for
various
diseases.
Recent
studies
demonstrated
that
extracellular
vesicles
(EVs)
released
by
MSCs
play
an
important
role
their
therapeutic
activities.
EVs
contain
a
variety
of
bioactive
molecules
such
as
proteins,
messenger
RNAs
(mRNAs),
and
micro
(miRNAs)
modify
the
function
recipient
transferring
these
molecules.
Despite
promising
potential
EV
substitute
MSC
therapy,
there
are
challenges
need
to
be
addressed
clinical
success
therapy.
quality
has
shown
vary
from
batch
preparation
preparation.
As
consistency
reproducibility
effects
rely
on
EVs,
it
is
necessary
establish
techniques
manufacture
scalable
amounts
with
same
quality.
In
this
manuscript,
we
discuss
factors
affect
We
then
introduce
pre-clinical
bone/cartilage
diseases
osteoarthritis,
rheumatoid
arthritis,
osteoporosis.
Pharmaceutics,
Год журнала:
2023,
Номер
15(2), С. 437 - 437
Опубликована: Янв. 28, 2023
Altered
cellular
metabolism
is
a
well-established
hallmark
of
cancer.
Although
most
studies
have
focused
on
the
glucose
and
glutamine,
upregulation
lipid
also
frequent
in
cells
undergoing
oncogenic
transformation.
In
fact,
cancer
need
to
meet
enhanced
demand
plasma
membrane
synthesis
energy
production
support
their
proliferation.
Moreover,
lipids
are
precursors
signaling
molecules,
termed
mediators,
which
play
role
shaping
tumor
microenvironment.
Recent
methodological
advances
analysis
prompted
aimed
at
investigating
whole
content
sample
(lipidome)
unravel
complexity
changes
patient
biofluids.
This
review
focuses
application
mass
spectrometry-based
lipidomics
for
discovery
biomarkers.
Here,
we
summarized
main
alteration
patients'
biofluids
uncovered
potential
use
early
detection
disease
treatment
selection.
We
discuss
advantages
using
biofluid-derived
extracellular
vesicles
as
platform
biomarker
discovery.
These
molecular
signature
that
fingerprint
originating
cells.
Hence,
cargo
has
emerged
promising
strategy
identification
sensitive
specific
biomarkers
compared
unprocessed
biofluid.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Март 8, 2023
The
conventional
therapeutic
approaches
to
treat
autoimmune
diseases
through
suppressing
the
immune
system,
such
as
steroidal
and
non-steroidal
anti-inflammatory
drugs,
are
not
adequately
practical.
Moreover,
these
regimens
associated
with
considerable
complications.
Designing
tolerogenic
strategies
based
on
stem
cells,
their
extracellular
vesicles
(EVs)
seems
open
a
promising
path
managing
diseases’
vast
burden.
Mesenchymal
stem/stromal
cells
(MSCs),
dendritic
regulatory
T
(Tregs)
main
cell
types
applied
restore
status;
MSCs
play
more
beneficial
role
due
amenable
properties
extensive
cross-talks
different
cells.
With
existing
concerns
about
employment
of
new
cell-free
paradigms,
EV-based
therapies,
gaining
attention
in
this
field.
Additionally,
EVs’
unique
have
made
them
be
known
smart
immunomodulators
considered
potential
substitute
for
therapy.
This
review
provides
an
overview
advantages
disadvantages
cell-based
methods
treating
diseases.
study
also
presents
outlook
future
EVs
implemented
clinics
patients.
Cancers,
Год журнала:
2023,
Номер
15(18), С. 4425 - 4425
Опубликована: Сен. 5, 2023
The
infiltration
of
primary
tumors
and
metastasis
formation
at
distant
sites
strongly
impact
the
prognosis
quality
life
cancer
patients.
Current
therapies
including
surgery,
radiotherapy,
chemotherapy
are
limited
in
targeting
complex
cell
migration
mechanisms
responsible
for
invasiveness
metastasis.
A
better
understanding
these
development
new
urgently
needed.
Extracellular
vesicles
(EVs)
lipid-enveloped
particles
involved
inter-tissue
inter-cell
communication.
This
review
article
focuses
on
EVs
released
by
tumor
cells,
specifically
We
first
introduce
processes
EV
subtypes,
we
give
an
overview
how
tumor-derived
(TDEVs)
may
migration.
Then,
discuss
ongoing
EV-based
therapeutic
approaches,
inhibition
general
EV-related
as
well
use
anti-cancer
drug
delivery,
focusing
harnessing
TDEVs.
propose
a
protein-EV
shuttle
route
alternative
to
secretion
or
membrane
binding,
influencing
downstream
signaling
final
effect
target
with
strong
implications
tumorigenesis.
Finally,
highlight
pitfalls
limitations
exploitation
that
must
be
overcome
realize
promise
therapy.
